Pulling SEC filings + quote and writing the call…

Artiva Biotherapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $-0.64 EPS
Last earnings -13.0% on 2026-05-08
Conservative balance sheet (liabilities/equity 0.19x); but revenue fell -100.0% YoY.
Artiva Biotherapeutics, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -76.3% ROE.
Sources: SEC EDGAR (CIK 0001817241, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 6:39:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $33.5M | $251K | $0.00 |
| Gross profit | — | — | — |
| Operating income | -$30.7M | -$67.3M | -$89.8M |
| Net income | -$28.7M | -$65.4M | -$83.9M |
| Diluted EPS | -$35.78 | -$5.81 | -$3.43 |
| Net margin | -85.8% | -26045.0% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Last 90 days: 8 open-market buys · 5 sales
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 125K @ $8.89 | $1.11M |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 15.4K @ $8.99 | $139K |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 391K @ $8.57 | $3.35M |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 549K @ $7.91 | $4.34M |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 103.00 @ $7.00 | $721.00 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 479K @ $6.91 | $3.31M |
| 2026-05-19 | Raymon Heather SVP, Research and Development | Sell | 3.10K @ $9.01 | $27.9K |
| 2026-05-19 | Horan Christopher Chief Tech Operations Officer | Sell | 7.00K @ $9.01 | $63.1K |
| 2026-05-19 | Bush Jennifer COO, CLO, Compliance Officer | Sell | 8.79K @ $9.01 | $79.2K |
| 2026-05-19 | Banerjee Subhashis Chief Medical Officer | Sell | 7.04K @ $9.01 | $63.4K |
| 2026-05-19 | Aslan Fred Chief Executive Officer | Sell | 27.1K @ $9.01 | $244K |
| 2026-05-11 | GC Corp. 10% owner | Buy | 1.09M @ $11.52 | $12.5M |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.